What is Illumina's market cap?

Illumina (ILMN) has a market capitalization of $28.4B and trades on NASDAQ.

What is Illumina's revenue and profitability?

Illumina generated $4.4B in trailing twelve-month revenue with net income of $853.0M, representing a net margin of 19.4%. Gross margin stands at 66.2%, with free cash flow of $974.0M. These figures are based on the Q1 2026 filing.

Who are Illumina's competitors?

Illumina's key competitors include Pacific Biosciences, Thermo Fisher Scientific, Twist Bioscience Corporation Common Stock, and others. These companies compete in similar markets and product categories.

What subsidiaries does Illumina have?

Illumina's subsidiaries include GRAIL.

Where is Illumina headquartered?

Illumina is headquartered in United States of America and employs approximately 9,300 people. It has been publicly traded since 2000.

Illumina

ILMN

Illumina is a global leader in sequencing- and array-based solutions for genetic and genomic analysis.

Market cap

$28.42B+78.1%

Revenue$4.4B+1.3%

Net income$853.0M+188%

Free cash flow$974.0M+11.2%

EPS (diluted)$5.50+168%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 30, 2026

Revenue$1.1BBeat by $17.8M EPS$1.15Beat by $0.10

Read the full report

Next report

Jul 30, 2026 (In 2 weeks)

Revenue estimate$1.1B

EPS estimate$1.24

Financials

Q1 2026

Income statement

See full

Revenue$1.1B+4.8%

Gross profit$721.0M+5.6%

Operating income$209.0M+27.4%

Net income$134.0M+2.3%

EPS (diluted)$0.87+6.1%

Balance sheet

See full

Cash & equivalents$1.1B-2.2%

Total debt$2.0B-3.0%

Total equity$2.7B+13.0%

Total assets$6.6B+6.1%

Cash flow

See full

Operating cash flow$289.0M+20.4%

CapEx$38.0M+18.8%

Free cash flow$251.0M+20.7%

Valuation & ratios

Valuation

See full

Market cap$28.42B+78.1%

Enterprise value$29.37B+71.5%

P/E33.3×+20.6×

P/S6.5×+2.7×

Profitability

See full

Gross margin66.2%-0.1pp

Operating margin19.4%—

Net margin19.4%+12.7pp

FCF margin22.2%+2.0pp

Returns & leverage

See full

Return on equity33.8%+23.9pp

Debt / equity0.8×-0.1×

Current ratio1.7×-0.1×

Segments

By geography

See full

United States and Canada$590.0M—

Europe, Middle East, Africa and Latin America$356.0M—

Asia-Pacific$93.0M—

By product

See full

Consumables$797.0M+3.8%

Service$174.0M+8.1%

Instruments$120.0M+7.1%

By segment

See full

Sequencing$995.0M+5.1%

Microarray$96.0M+2.1%

Competitors

By market cap

Thermo Fisher Scientific$189.58B+17.0%

Agilent Technologies$36.5B+5.7%

Illumina$28.4B+78.1%

Revvity$12.2B+2.2%

Twist Bioscience Corporation$5.6B+143%

Azenta$1.1B-25.7%

Pacific Biosciences of California$465.9M-3.0%

Standard BioTools Inc.$345.1M-29.2%

By revenue growth

Twist Bioscience Corporation+17.8%

Agilent Technologies+9.1%

Pacific Biosciences of California+5.0%

Revvity+4.8%

Thermo Fisher Scientific+2.4%

Illumina+1.3%

Azenta-5.9%

By net margin

Agilent Technologies19.55%+2.0pp

Illumina19.42%+41.7pp

Thermo Fisher Scientific15.19%+0.4pp

Revvity8.26%-2.1pp

Twist Bioscience Corporation-19.85%+35.1pp

Azenta-29.06%-17.7pp

Pacific Biosciences of California-80.34%+353pp

Profile

Illumina is a global leader in sequencing- and array-based solutions for genetic and genomic analysis. The company provides integrated systems, consumables, and analysis tools that enable researchers and clinicians to study genetic variation and biological function. Its core value proposition lies in accelerating the adoption of precision medicine through high-throughput, cost-effective genomic technologies.

Competitive position

Illumina is the dominant market leader in next-generation sequencing (NGS), characterized by a massive installed base and a high-margin recurring revenue stream from proprietary consumables.

GeographiesNorth America, Europe, Asia-Pacific, China, Latin America

Customer segmentsAcademic and Government, Biopharma, Clinical Diagnostics, Applied Markets

Business modelRazor-and-blade, Manufacturing, Professional Services, SaaS

SuppliersChemical and biochemical material suppliers, Electronic component manufacturers, Single-source raw material providers, Cloud infrastructure providers

CustomersAcademic research institutions, Clinical diagnostic labs, Pharmaceutical R&D departments, Agricultural biotechnology firms, Direct-to-consumer genetic testing companies

CountryUnited States of America

Listed2000

Employees9.3K

CEOJacob Thaysen

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websiteillumina.com

FilingsSEC EDGAR

Ask your AI about Illumina.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Illumina's market cap?: Illumina (ILMN) has a market capitalization of $28.4B and trades on NASDAQ.
What is Illumina's revenue and profitability?: Illumina generated $4.4B in trailing twelve-month revenue with net income of $853.0M, representing a net margin of 19.4%. Gross margin stands at 66.2%, with free cash flow of $974.0M. These figures are based on the Q1 2026 filing.
Who are Illumina's competitors?: Illumina's key competitors include Pacific Biosciences, Thermo Fisher Scientific, Twist Bioscience Corporation Common Stock, and others. These companies compete in similar markets and product categories.
What subsidiaries does Illumina have?: Illumina's subsidiaries include GRAIL.
Where is Illumina headquartered?: Illumina is headquartered in United States of America and employs approximately 9,300 people. It has been publicly traded since 2000.